NDAORALTABLETPriority Review
Approved
Jul 1966
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
LASIX (furosemide) by Bausch Health is clinical pharmacology investigations into the mode of action of lasix have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. First approved in 1966.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX (furosemide) is a loop diuretic approved in 1966 that inhibits sodium and chloride reabsorption primarily in the loop of Henle, proximal, and distal tubules. It is indicated for heart failure, hypertension, renal impairment, pulmonary edema, and volume overload across multiple disease states. The drug achieves diuresis within 1 hour with peak effect in 1-2 hours and a 6-8 hour duration of action.
$0.61MPart D
LOE ApproachingStable
Mature, high-volume generic product with stable but limited growth trajectory and declining brand team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Investigations into the mode of action of LASIX have utilized micropuncture studies in rats, stop flow experiments in dogs and various clearance studies in both humans and experimental animals. It has been demonstrated that LASIX inhibits primarily the absorption of sodium and…
Worked on LASIX at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.